their lifespan greater advances in medicinal treatment than have occurred in all the previous aeons of time, and there is no saying what the majesty and splendour of its progress will be in the remaining years of the century. Perhaps we will be able to prevent the common cold! Young physicians nowadays, armed with the therapeutic thunderbolts of Jove which the synthetic chemist has' put into their sometimes rather ungodlike hands, must find it difficult to imagine, just as elderly physicians are beginning to find it difficult to remember, what it was like to practise medicine when there was no insulin, vitamin B12, suiphonami des, antibiotics, specifics for tropical disease, hypotensives, anticoagulants and potent hormones, diuretics and anticonvulsants.
The innovation of drugs The discovery of drugs is popularly supposed to derive from the sheer intellectualism and genius of the research worker who has planned his research with a certain objective in view. Sir Henry Dale's work on histamine and acetyl choline and Sir Rudolph Peters' introduction of dimercaprol (British anti-lewisite) are indeed elegant examples of this planned intellectual approach, but they are uncommon.
As has been said, early pharmacological advances stemmed from the discovery of the biodynamic agents in naturally occurring substances, culled from the hedgerows, so to speak: from the poppy, the foxglove, the cinchona bark, the coca leaf, the rye fungus and so forth. The isolation of their active principles resulted in morphine, digoxin, quinine, cocaine and ergotoxin. Then by ingenious chemical juggling with the molecule, new substances evolved. Thus, attempts to simplify the complex molecule of quinine, which had been isolated as the active principle of the cinchona bark, resulted in quinidine, and the synthetic antimalarials, and Bovet studying the pharmacological actions of the latter found quite unexpectedly that they had antihistamine effects; hence the antihistamine drugs. The original antihistamines, particularly diphenhydramine (Benadryl) were markedly soporific and prevented travel sickness; hence the phenothiazine tranquillizers and the modern antiemetics. Thus, all these drugs: quinine, quinidine, the synthetic antiplasmodials, the antihistamines, the tranquillizers and antiemetics derive from the seventeenth century remedy, Jesuit's bark.
There are many other examples of this pharmacological house-that-Jack-built, such as the rye fungus, ergot, the ergot alkaloids, methysergide and lysergic acid (LSD), that most controversial of hallucigenic agents which may, however, have loosened a chink in the casement opening on the mechanism of disturbed mental processes and the biochemistry of mood.
It is a sobering reflection that many important advances have been due topure serendipity:
fortuitous observations acting on the prepared mind like the famous discovery of penicillin; but sometimes also from fallacious hypotheses. For example, in 1857 bromide was advocated for the prevention of juvenile epilepsy, not for its depressant action on the cerebral motor Cortex -subsequently demonstrated -but because it was a well known anaphrodisiac and masturbation was then thought to be an important aetiological factor in juvenile epilepsy, a threat that caused grave concern to generations of Victorian schoolboys. In this century, Minot and Murphy introduced liver for the treatment of pernicious anaemia because dogs they had rendered anaemic by repeated bleedings were found to recover from their anaemia more rapidly on a diet of liver than on any other foodstuff; this was because of liver's very high iron Content, which had nothing to do with its ability to convert a megaloblastic into a normoblastic bone marrow. Lastly, in 1936 Domagk, after years of study on dyes, introduced prontosil rubrum for the treatment of haemolytic streptococcal infections; its great efficacy in this respect had of course nothing to do with it being a dye, but because quite fortuitously it happened to contain the sulphanilamide grouping. Many valuable new remedies have developed from the observation, again acting on prepared minds, of the unexpected side effects of well known drugs: mersalyl, the thiazide diuretics, the hypoglycaemic sulphonylureas, the phenothiazine tranquillizers and the antidepressants were all developed in that way. Some recent advances have resulted from an enlightened screening process by industry in which numbers of compounds, synthesized because of their known value in certain conditions, are screened to ascertain their possible value in others. Thus, the hypotensive drug guanethidine was discovered by studying agents of value in the treatment of trypanosomiasis; probenecid, originally synthesized to delay the tubular excretion of penicillin, has been used more recently to increase the tubular excretion of uric in the treatment of gout; and acetazolamide (Diamox), introduced as a diuretic, is now seldom used for that purpose but is of value in the management of glaucoma.
Perhaps, however, the most popular modern method of pharmaceutical innovation consists in modifying the molecular structure of preparations with a recognized pharmacological action in the hope that the modification will produce a more potent, safer or cheaper drug than the original. This method of minimal molecular manipulation -molecular roulette -particularly when undertaken to circumvent patents, has been justifiably criticized for flooding the market with a multitude of preparations differing insignificantly from each other and called by a bewildering number of brand names which has proved an embarrassment to our profession. Nevertheless, such 'me too' drugs -as they are often disparagingly called -should not be unduly denigrated for, just as the 1978 automobile has gradually evolved from slight changes over the years on earlier models, so modern pharmaceuticals often constitute great improvements on their originals. Which of us, for example, would now use the early sulphonamides in preference to their modern counterparts or, except perhaps for replacement purposes, the original cortisone in preference to modern corticosteroids?
The benefits of modern drugs
It is superfluous to elaborate on the great benefits to society conferred by modern drugs. The average expectation of life of a newborn baby has increased since the beginning of the century by 25 years. Early in the century this was mostly due to improved hygiene, housing and nutrition, but in the last thirty or forty years mostly to modern drugs. Quite apart from their beneficial effects on mortality statistics, the relief from suffering resulting from their purely symptomatic use and the saving to our economy due to diminished morbidity are vast but more difficult to compute. It has, however, been estimated with some accuracy that the saving to our economy resulting from the use of modern antituberculosis remedies alone is about £55 million a year.
As the result of all this the pattern of disease as we see it today has changed out of recognition in the last thirty or forty years: most hospitals for tuberculosis have been closed, and many wards for infectious disease have been closed or given over to the care of old people; young people between the ages of 15 and 30 relatively seldom die from disease nowadays; the chief cause of death in this age group is accident (mostly on the roads), the second is suicide, and the third (a long way behind) is the comparatively rare group of blood diseases -the acute reticuloses, including acute leukaemia; the atmosphere and length of stay in our mental hospitals have improved out of recognition owing to use of modern psychotropic drugs; the great modern advances in surgery have only been made possible by advances in chemotherapy, including modern anaesthesia; and our medical wards in general hospitals are now mostly filled with patients suffering from what might be called the natural processes of ageingvarious forms of atherosclerosis of the cerebral, coronary and renal arteries.
Nor has it been only in developed countries that these great benefits have resulted, for specifics are banishing various tropical diseases from vast tracts of the globe. It must be confessed that this is exacerbating the greatest problem facing mankind today -that of his terrifying multiplication. Thus the contraceptive pill may represent the most important recent advance in pharmacology and, as yet at any rate, Nature does not seem to be exacting an excessive retribution. It is profoundly to be hoped she will not do so in the future.
The drawbacks to drugs
The old-fashioned bottle of medicine, though relatively ineffective, was comparatively innocuous, while the modern drug is powerful for good but also for evil. III health due to drugs -iatrogenesis -has become a new dimension in the aetiology of disease. Perhaps IO/~of Ourpatients suffer to a greater or lesser extent from our efforts to treat them (Davies 1977) .Our powers over Nature in this as in other respects have advanced so far that Nature seems to have become retaliatory and to be exacting a considerable retribution. Unless, however, a drug can modify or suppress biological processes it will be useless in treatment; but if it has this ability it is bound in the nature of things to cause adverse reactions from time to time. There are no entirely safe drugs that work, and those who say that nothing but their complete safety will sufficedemand the impossible. The public who desire progress must be prepared for some risk. They have always accepted the not inconsiderable risks of surgery to which some modern drugs are equivalent in efficacy. They shudder at a death rate of, say, I in 50 000 patients dying as the result of taking a usually valuable remedy (and which surgeon, incidentally, would not be enchanted with such statistics for the most minor operation?) but are more complacent about the far greater risks of cigarette smoking, alcoholism or death on the roads. Yet, with propriety, wisdom and skill in their prescription and use, combined with sensible control regulations, the dangers of drugs would be minimized.
In this respect our profession has not been entirely blameless. We must confess that there is a considerable amount of excessive, unwise and sometimes irresponsible prescribing in this country, though to a less extent than in most other countries in the Western world. There are many reasons for this. First, there is the insatiable demand for medicines by the public, for the desire to take medicine isthe chief thing which differentiates man from the lower animals; in this respect we tend to pander too much to the public's 'wants' rather than to what we think are their 'needs'. Secondly, until recently at any rate, there were too few doctors in this country with its increasing population, so that most are busy and some overworked. While it takes a long time to elicit a clinical history, to conduct a physical examination and to give wise advice, it only takes a moment to write a prescription which often pleases and satisfies the patient. Thus, in our overcrowded hospital outpatient departments and practice surgeries we have all probably sometimes prescribed unnecessarily in order to get luncheon or supper; and once started the habit is apt to grow. Thirdly, prescribing is often injudicious due to insufficient undergraduate and postgraduate instruction on the subject, in the past at any rate. Until recently in most medical schools pharmacology was taught entirely as a preclinical science. Such'academic pharmacology is a valuable scientific discipline. It is, however, impossible to teach the therapeutic use of drugs at this stage of the student's career, when he knows nothing about pathology or patients. Fortunately, in recent years most medical schools in the UK have established departments of clinical pharmacology to teach undergraduates the use of the formidable tools of their trade. Further, all over the country centres of postgraduate education have sprung up, an essential part of whose activities is the continuing education of the doctor in prescribing. Lastly, as a factor in over-prescribing there is the formidable, insistent and skilful promotion of drugs by the pharmaceutical industry some of which, in the past at any rate, was SUbject to justifiable criticism.
the pharmaceutical industry
. The great advances in chemotherapy in the last 40 years have, with some notable exceptions, been due to scientists working in the laboratories of the pharmaceutical industry. The industry seems to possess all the conventional commercial virtues: a high rate of investment; satisfactory labour relationships; a good record of supplying customers in periods of epidemics or individual emergency; a large expenditure of money on fundamental as well as applied research; generosity in benefactions to charity and in support of medical, veterinary, dental and agricultural advancement; and a brilliant record of commercial success which during 1976 Contributed £350 million to our export drive. A measure of the innovative genius of industry is that of the ISO most popularly prescribed drugs last year only 22 were known in 1946.
Thus, it is somewhat surprising that few other industries have been subjected to such adverse criticism, jealous political antagonism or stringent political controls. The main reasons for the undoubted unpopularity of the industry are that its profits are thought to be too great, its promotion of drugs excessive and inaccurate, and that it battens on human fear, gullibility and sutTering.
. It would take too long to canvass the arguments advanced on each side of these controversies. Suffice it to say that in some future Utopia non-profit-making motivations may achieve the same results without side etTects. Till then we must take the world as we find it and remember that since the October Revolution the state-owned industries in the USSR and its satellites have hardly produced a single new therapeutic agent of importance. It would be a pity to kill the goose which laid so many golden therapeutic eggs by excessive bureaucratic restrictions -still worse by nationalization.
The introduction of new drugs
Long and laborious pharmacological experiments on animals which may fail at many stages precede the introduction of new therapeutic agents. Such animal tests are of course essential before a new drug is given to human beings, and they may tell us something of its efficacy when the animal model can be made to develop the same disorder as occurs in man. They tell us a lot about a drug's absorption, transport, metabolism and excretion; and a little about its possible carcogenicity and teratogenicity. Nevertheless, ditTerent species of animals react quite ditTerently to ditTerent drugs. Man is a distinct species and some medicines which are extremely toxic to humans may be relatively harmless to an animal and vice versa. We must eventually proceed to clinical trials of medicines on humans.
Clinical trials of drugs are of course as old as medicine: when the first doctor decided to ring the changes in treatment from the fillet of a fenny snake to the eye of a newt or the toe of a frog, and to observe the result, that was a clinical trial. A question was asked of Nature and impressions followed; haphazard impressions largely conditioned by the dogma of contemporary teaching. Millions of such experiments by hundreds of thousands of doctors on billions of patients produced very few or very slow results, so that bleedings, sweatings, vomitings and purgings persisted as good treatment for hundreds of years.
The modern controlled clinical trial of drugs, introduced by Sir Austin Bradford Hill in 1945, is a purely English contribution to medicine. The word 'control' does not appear in medical literature till 1890, and only in the last few decades has modern medical science been conducting clinical trials of drugs constantly tested by accurate observation and statistical analysis, in which efforts are made to avoid bias in allocation and bias in evaluation. Such trials have produced accurate results with remarkable rapidity. Ethical problems, however, always arise with clinical trials of new drugs and it is odd that there is a widespread feeling that the medieval type of trial which persisted till about forty years ago was ethically more acceptable than the modern ones. Edward Jenner administered lethal smallpox toxin to that little boy just because he had a 'hunch' that his previous vaccination of him with cow pox would afford protection. Nevertheless, modern clinical trials are apt to be regarded as treating patients as if they were guinea-pigs. There must always be a patient or group of patients who receive a new drug for the first time. Surely it is desirable that this should happen under careful observation by experts in hospital, and that the experience of such patients should be made of value to their successors.
Numerous efforts have been made to lay down rigid rules to control all the diverse circumstances of clinical trials, but the ultimate judge of what is justifiable in human experimentation is not a rigid code of ethics but the conscience of the doctor, which should be a tender one, and the consciences of his colleagues, with whom he should always consult as to the propriety of his actions. The end does not always justify the means and the good things that a man does can only be made complete by the things he refuses to do.
The control of drugs There is a general consensus that the sole responsibility for the safety and efficacy of drugs cannot be left entirely to the manufacturer or prescriber. Nevertheless, it is difficult to know how far government should go in assuming this responsibility without interfering unduly with scientific advance, the wellbeing of the pharmaceutical industry and the cherished freedom of the doctor, dentist and veterinary surgeon to prescribe as they think best. Inadequate regulation can prejudice public safety but excessive regulation can also be prejudicial. Certainly government should control the purity and strength of drugs reaching the market and should try to ensure that they are effective and reasonably safe for the purposes for which they are to be used. Many doctors, however, might justifiably object to direction as to how and for what purpose these drugs should be used, for doctors are not paid to dispense the treatment laid down by governmental committees. It may be rather surprising to some that the situation was best put by that remarkable man Aneurin Bevan: 'Any Health Service which hopes to win the consent of doctors must allay the fear that bureaucratic interference will affect professional freedom and come between the doctor and his patient. ... It is for the community to provide the apparatus of medicine for the doctor. It is for him to use it freely in accordance with the standards of his profession and the requirements of his oath.'
The statement that medicine is international and knows no frontiers is subject to many qualifications. Certainly drug control regulations in different countries are extremely variable. Some have had drug controls of some sort for a long time. Others have only instituted them very recently. There are none at all in many underdeveloped countries.
Ever since the first British Pharmacopoeia was published in 1864, successive governments in the UK have been active in producing regulations to control the purity and strength of drugs, to stop charlatans from deluding the public by quack advertisements for the cure of serious diseases, to prevent the counter sale of certain medicines without a prescription, and to control the risk of addiction to potent narcotics. Only in recent years, however, since the thalidomide disaster, has our regulatory attention been focused on the safety and efficacy of drugs.
The first American legislation on drugs was the Pure Food and Drug Act of 1906, primarily concerned with the prevention of misbranding and adulteration of products. The subsequent 1938 Food, Drug and Cosmetic Act provided the first governmental power in the world to rule on the safety of medicines, preceding in this respect our own legislation by a quarter of a century. In 1961, as the result of Senator Kefauver's congressional hearings, amendments were made to the 1938 Act; these imposed far greater responsibilities on the Food and Drug Administration (FDA) which now had to license new medicines not only for their safety but also for their efficacy, undertake a retrospective evaluation of all medicines marketed from 1938onwards, and much else. For their colossal task in the USA, the FDA -the most powerful drug regulatory agency in the world -has become a vast bureaucratic organization.
In Britain ultimate power to license medicines rests with the Ministers of Health and Agriculture, responsible to Parliament. They act on the advice of the Safety of Medicines Committee which has a number of sub-committees, and of the Medicines Commission. The membership of these organizations consists of very part-time, virtually honorary professional men -scientists, physicians, pharmacists and veterinarians -whose careers do not depend on their membership of these bodies, on which they serve largely as an altruistic chore. They are, of course, assisted by an increasing staff ofexpert civil servants who do most of the preparatory Work, but the decisions are not taken by the civil servants. Somewhat similar regulatory organizations exist in Canada, Australia, New Zealand and Eire.
On the other hand, in the USA ultimate power to license medicines rests with the full-time professional civil servants of the FDA. They take the decisions though they often take advice from outside professional experts. It is odd that in the USA, the home of big business and free enterprise, they should have been far more bureaucratic in their control of medicines -until recently at any rate -than we have been in the UK with our so-called socialized medicine. The regUlatory drug control authorities in European countries mostly follow the example set by the FDA, to a greater or less extent.
An official charged with approving or disapproving a new drug can make two kinds of mistake: he can approve one that turns out to be unduly toxic, in which case his folly will be emblazoned publicly and he will be disgraced; or he can refuse approval of one that could have been life saving, in which case few will know about it and those whose lives might have been saved will not be there to protest. No wonder such officials are apt to become very chary of approving a new drug, and tend to think up yet another test on it before "risking their reputation. Consequently the time now taken to get a new chemical entity approved by the FDA is usually about seven years and sometimes considerably longer, and the cost has rocketed to millions of dollars (Hansen 1977 , Wardell 1974 . As a result, many pharmaceutical firms cannot afford to produce new drugs whose market potential does not seem likely to cover the cost of getting them licensed. In the last 15 years there has thus been a great fall in the number of new chemical entities produced. Sometimes also some quite valuable drugs have been available for years in the UK before they have been able to be marketed in the USA. In this respect it is interesting to speculate how many thousands of deaths would have occurred from pneumococcal pneumonia had it taken seven years and cost nine million dollars to license sulphapyridine (the famous old M & B 693).
We must not be too complacent about all this. Nowadays what the USA does today we tend to do tomorrow. Since our 1968 Medicines Act and the licensing of drugs came under the law it has taken far longer to put a new drug on the market in this country than used to be the case. This particularly applies to the preliminary experiments on animals which on the whole are required to be more searching and protracted here than anywhere else, especially those for teratogenicity. Tests for teratogenicity are mostly very unreliable. Why then do we do them? The answer is that they are better than nothing. But are they? They cost the taxpayer large sums in money and manpower and are often relatively valueless.
By requesting a repetition of pharmacological and clinical studies already done in other countries, even when these have been performed according to acceptable standards, a great deal of time, money and manpower is often wasted.
It is possible that any increased safety of drugs achieved by the stringent regulations required nowadays is outweighed by the delay and expense of introducing, or even postponing altogether, valuable new remedies.
The adverse reactions to drugs causing most current concern, as with practolol, are those which arise some years after the marketing of a new medicine. No matter how meticulous the preparatory work of the pharmacologist and clinician may be, there is ultimately no substitute for years of experience in the use of the drug in practice. No formal clinical trial can be large enough to exclude unforeseeable, rare but possibly very serious toxic effects occurring, say, once in a few thousand patients. A shift of requirements is therefore necessary from further elaboration of preregistration tests to effective systems of monitoring after marketing. The spontaneous reporting by clinicians of suspected adverse reactions on yellow cards to the Safety of Medicines Committee has not proved adequate for the purpose. Several different procedures of this type of surveillance have been advocated by competent authorities recently (Dollery & Rawlins 1977 , Inman 1977 , Lawson & Henry 197 7 , Wilson 1977 . The scheme of Lawson & Henry is particularly appealing, as it avoids those problems inherent in the registration of patients by the prescribing doctor, transferring some work from him to the pharmacist. Given an estimated compliance rate of only 50"" of pharmacists it would provide a vast and truly random sample of the population at risk. When operative, one or other of these schemes, perhaps appropriately modified, might well allow new important drugs to be marketed more expeditiously and without jeopardizing their safety.
